OBJECTIVE: Intracranial artery stenosis can be fatal, requiring fast, safe and effective intervention. The introduction of the Wingspan™ stent system with Gateway™ percutaneous transluminal angioplasty balloon catheter has made intracranial intervention possible in a clinical trial setting. This systematic review planned to identify and review all randomized controlled trials comparing angioplasty and stenting of intracranial arteries with standard medical care. METHODS: Electronic databases and relevant records were examined for possible trials using predefined inclusion and exclusion criteria. RESULTS: A total of 3661 records were identified by searching several English language databases and other sources including Chinese academic journals. The recently discontinued Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis (SAMMPRIS) trial was the single qualifying study and showed clear advantage of medical management over percutaneous transluminal angioplasty and stenting (PTAS). CONCLUSIONS: The SAMPRASS trial indicated that PTAS is associated with high complication and morbidity rates. Definitive recommendations cannot be made until convincing results from additional robustly designed randomized trials become available.
Introduction
Intracranial artery stenosis is a common cause of ischaemic stroke. 1 Patients with intracranial atherosclerosis are classed as symptomatic or asymptomatic. The risk factors for the development of intracranial atherosclerotic disease are broadly classified as unmodifiable (e.g. age, gender); modifiable, which are well documented (e.g. hypertension, total serum cholesterol); and potentially modifiable factors, which are less well documented (e.g. diabetes mellitus, metabolic syndrome). 2 Ethnicity accounts for significant variation in the incidence of the disease in symptomatic patients, but the effect of ethnicity in asymptomatic patients is not clear. The Northern Manhattan Stroke Study showed that the annual age-adjusted incidences for first ischaemic stroke were 88, 149 and 191 per 100 000 in Caucasian, Y Zhou, Q-W Yang, H-Y Xiong Stenting for intracranial artery stenosis: a systematic review Hispanic and Black populations, respectively. 3 A study involving 705 Chinese patients revealed 49% to have occlusive arteries, but only 37% had intracranial lesions. 4 Patients who experience a stroke or transient ischaemic attack due to a stenosis of 50 -99% have traditionally been treated with antithrombotic medication. Even with this treatment there remains a 12 -14% risk of further stroke in the subsequent 2 years, increasing to 20% in at-risk individuals. 2 Trials comparing antithrombotic medications with anticoagulants for prevention of stroke or vascular events have not generated satisfactory results and, worse still, have been associated with high rates of bleeding. 5 Intracranial angioplasty (with or without a stent) was developed as a treatment option for patients with symptomatic intracranial atherosclerotic disease. Early intracranial angioplasty techniques for percutaneous coronary intervention used balloons, followed by balloon-mounted intracranial stents, 2,6 but this was associated with high technical failure rates. 7 In 2005, the Wingspan™ stent system with Gateway™ percutaneous transluminal angioplasty balloon catheter (Boston Scientific SMART, San Leandro, CA, USA) was approved by the US Food and Drug Administration for the treatment of intracranial atherosclerotic disease with > 50% stenosis. 8 Studies on the use of stentassisted angioplasty for atherosclerotic intracranial artery stenosis have demonstrated its effectiveness, 9 but the majority of these studies have been case reports or small scale clinical studies. Intracranial stent-assisted intervention is associated with several complications, including the formation of blood clots, thromboembolism, vascular rupture, and dissection and vascular vessel re-narrowing in the long-term. 10 The reported risk of stroke and death during the procedure itself varies between 0% and 30%. 11, 12 The high complication risk prompted this systematic review of the available literature to determine the effectiveness of intracranial angioplasty with stenting for treatment of intracranial atherosclerosis.
Materials and methods

ELIGIBILITY OF STUDIES
All randomized controlled trials, including those described as 'double-blind' with implied randomization, were considered for inclusion in this systematic review. Quasirandomized studies were excluded. Participants were patients who had symptomatic intracranial atherosclerosis defined as > 50% stenosis (determined by conventional angiography). Trials were excluded in the following cases: (i) angioplasty or stenting was part of the treatment for acute ischaemic events due to acute vessel occlusion; or (ii) angioplasty was performed in the absence of a stenting procedure. Studies that did not use stent placement following angioplasty were also excluded. Angioplasty with stenting together with standard medical care was compared with standard medical care alone. Multiple publications from the same trial were counted as a single trial.
The primary outcome of interest was the occurrence of postintervention stroke. Secondary outcomes included hospital admission, length of hospital stay, adverse events, quality of life, cost of treatment and patient satisfaction.
SEARCH STRATEGY
An electronic search was performed in March 2011 of Chinese academic journals and the following English language databases: MEDLINE, CINAHL (Cumulative The reference lists of all identified potentially relevant papers were searched for further studies. Authors were contacted for any additional studies and unpublished data. This investigation was supplemented with internet searches for additional clinical trials, unpublished research and/or grey literature. Websites were searched with a specific focus on clinical trial registries, in particular 'ClinicalTrials.gov'.
DATA COLLECTION AND STATISTICAL ANALYSES
Results were examined independently and those fulfilling the inclusion criteria were classified in the 'included studies' section, with the remainder recorded under the 'excluded studies' section. Disagreements were resolved following discussion. Review Manager version 5.1 (The Nordic Cochrane Centre, The Cochrane Collaboration 2011, Copenhagen, Denmark) was used to enter results of the search.
Results
The search strategy identified 3491 citations in the English language databases. A further 170 additional records were identified via other sources including Chinese academic journals, giving a total of 3661 citations. Of these, 574 were duplicates and were therefore excluded. A total of 3087 citations were inspected in electronic form and 2997 were excluded based on the title or abstract. The full text of 90 publications was examined. These 90 publications related to 20 studies or trials, many of which had generated multiple publications. None of these 20 studies met the inclusion criteria and were therefore excluded. How the studies were recorded as the systematic review progressed is outlined in Fig. 1 .
The full text of the 90 articles relating to the 20 excluded studies was examined in order to make a final decision regarding exclusion. The majority of excluded articles reported data from trials that studied the extracranial course of the carotid artery. The full text of these trials was examined to ensure that there were no useful data on stenting related to the intracranial section of the artery. 13 -32 Reasons for exclusion are outlined in Table 1 .
The Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis (SAMMPRIS) trial 33 ( Table 2) has recently reported results and was included in the analysis. This trial included a total of 451 patients, with 227 receiving medical management and 224 receiving percutaneous transluminal Y Zhou, Q-W Yang, H-Y Xiong Stenting for intracranial artery stenosis: a systematic review angioplasty and stenting (PTAS). The study was terminated early due to the risk of stroke or periprocedural death in the PTAS group and the results of a futility analysis that demonstrated virtually no benefit in the PTAS group had the trial been completed. The primary endpoints of the study were: (i) ischaemic stroke in the qualifying artery and other territory within 30 days of enrolment; (ii) nonstroke related death within 30 days of enrolment; and (iii) ischaemic stroke in the territory of the qualifying artery more than 30 days after enrolment. These endpoints were reached by 20.5% of patients in the PTAS group compared with 11.5% in the medical management group (relative risk [RR] 1.79, 95% confidence interval [CI] 1.15, 2.80; P = 0.009). The risk of any stroke was also significantly higher in the PTAS group (RR 1.58, 95% CI 1.06, 2.37; P = 0.03). There were no significant between-group differences in the incidence of major nonstroke related haemorrhage (4.5% of PTAS patients versus 1.8% of medically managed patients) or disabling or fatal stroke (8.5% of PTAS patients versus 5.7% of medically managed patients). An additional ongoing study, the Vertebral Artery Stenting Trial (VAST), may generate useful data on the effectiveness of intracranial interventions. 34 The characteristics of this study are outlined in Table 3 .
Discussion
The effective management of patients with intracranial arterial stenosis requires an No studies eligible for inclusion in meta-analysis Y Zhou, Q-W Yang, H-Y Xiong Stenting for intracranial artery stenosis: a systematic review intervention that is safe, effective and has minimal complications. The Warfarin-Aspirin Symptomatic Intracranial Disease Study found that patients with symptomatic intracranial vertebral or basilar arteries were at a high risk of developing stroke, myocardial infarction or death, 35 allowing the subsequent identification and correction of risk factors. A further trial revealed a potential benefit for aspirin compared with warfarin and the study was terminated early due to the potential risks to the warfarin group. 5 There were significantly fewer adverse effects in the aspirin group compared with the warfarin group (death 4.3% versus 9.7%; major haemorrhage 3.2% versus 8.3%; myocardial infarction 2.9% versus 7.3%; all comparisons P < 0.05), leading to the recommendation of aspirin as the preferred treatment for symptomatic intracranial arterial stenosis. 5 Subsequent research has shown that, despite medical treatment, the risk of complications from intracranial haemorrhage, 36 recurrence of ipsilateral stroke or vascular death 36 remains high, suggesting that alternative interventions are required in addition to medical management.
A review of stent-assisted angioplasty for symptomatic atherosclerotic intracranial 15 No useable data on the intracranial section of the vertebral artery CREST (Brott et al., 2010) 16 No data on intracranial vessels EVA 3S (Mas et al., 2006) 17 Intracranial arterial stenotic patients were excluded GESICA (Mazighi et al.,
Not randomized 2006) 18 ICSS (Bonati et al., 2010) 19 No useable data on the intracranial section of the carotid artery Liu et al., 2009 20 No useable data on the intracranial section of the carotid artery Marks et al., 2006 21 Not randomized McKevitt et al., 2003 22 Patients with symptomatic common carotid artery stenosis NASCET (Macdonald et Patients with symptomatic common carotid artery stenosis al., 2010) 23 Naylor et al., 1998 24 Patients with symptomatic internal carotid artery stenosis -not intracranial Qureshi 2004 25 Not randomized SAPPHIRE (Stolker et al., 2010) 26 No useable data on the intracranial section of the carotid artery Soo et al. 2010 27 No useable data available prior to first crossover SPACE (Ringleb and Hacke, No useable data on the intracranial section of the carotid artery 2007) 28 Steinbauer et al., 2008 29 Patients with carotid artery stenosis -not intracranial TESCAS-C (Ling and Jiao, No useable data on the intracranial section of the carotid artery 2006) 30 Witt et al., 2007 31 Patients with carotid artery stenosis -not intracranial Brooks et al., 2004 32 No useable data on intracranial part of carotid artery Y Zhou, Q-W Yang, H-Y Xiong Stenting for intracranial artery stenosis: a systematic review at least one of the following additional criteria to qualify for the study in order to increase the likelihood that the symptomatic intracranial stenosis was atherosclerotic: (i) insulin dependent diabetes for ≥ 15 years (ii) at least two of the following atherosclerotic risk factors: hypertension (blood pressure > 140/90 mmHg or antihypertensive drug treatment); dyslipidaemia (low-density lipoprotein > 130 mg/dl, high-density lipoprotein < 40 mg/dl, fasting triglycerides > 150 mg/dl, or lipidlowering therapy); smoking; noninsulin dependent diabetes or insulin dependent diabetes of < 15 years duration; family history of myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, stroke, carotid endarterectomy or stenting, or peripheral vascular surgery in parent or sibling (aged < 55 years for men or < 65 years for women at the time of the event) (iii) history of myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, carotid endarterectomy or stenting, or peripheral vascular surgery for atherosclerotic disease (iv) stenosis of extracranial carotid or vertebral artery, another intracranial artery, subclavian artery, coronary artery, iliac or femoral artery, other lower or upper extremity artery, mesenteric artery, or renal artery, documented by non-invasive vascular imaging or catheter angiography and considered atherosclerotic (v) aortic arch atheroma documented by noninvasive vascular imaging or catheter angiography (vi) aortic aneurysm documented by noninvasive vascular imaging or catheter angiography and considered atherosclerotic 6 Negative pregnancy test (in women who have menstruated in the previous 18 months) 7 Willing and able to return for all follow-up visits required by the protocol 8 Available by telephone 9 Understands the purpose and requirements of the study, can make him/herself understood, and has provided informed consent Interventions
Angioplasty and stenting with aggressive medical management versus medical management alone Y Zhou, Q-W Yang, H-Y Xiong Stenting for intracranial artery stenosis: a systematic review artery stenosis showed that, although stentassisted intracranial angioplasty was effective, its safety has yet to be proven. 37 That review did not include any randomized controlled trials and was not strictly systematic, but a Cochrane systematic review carried out in 2006 did not identify any randomized trials that could have been included. 38 A considerable number of trials have evaluated carotid artery stenting compared with carotid endarterectomy. 13, 39 These approaches have not been feasible in intracranial vessels until fairly recently due to the difficulty in accessing this part of the vasculature (including the distal part of the vertebral artery). Although the technical success rate of intracranial access is improving, the rate of complications remains high; non-randomized studies have shown a fatality rate of 3.2% and a risk of neurological complications of approximately 17.3%. 10 These studies have inherent bias, however, and it is possible that these rates would be even higher in randomized settings. 10 Given the inherent difficulties of the areas to be treated, various other interventions have been explored but with little evidence of success.
The International Extracranial-Intracranial Bypass Trial demonstrated that, although there was promise of benefit in the short term, long-term results identified a significantly increased risk of harm in the patients treated with surgery compared with medical interventions. 40 The ongoing Japanese Extracranial-Intracranial Bypass Trial aims to demonstrate whether surgical interventions would be effective in an intracranial arterial stenotic subset of patients. 41 Recent advances in technology and the introduction of predilation with an undersized Gateway™ balloon catheter and deployment of self-expanding Wingspan™ stents have increased expectations for a breakthrough in technology. This procedure allows the delivery of drug-eluting stents, providing advantages compared with bare metal stents, and has lead to the possibility of testing the effectiveness of these interventions in a clinical setting. 8, 9 The results of the SAMMPRIS trial have major implications for the safe management of patients. 33 The study showed a clear benefit of aggressive medical management, with the unacceptably high risk of stroke or 34 If the data show a clear benefit of medical management, then research ethics committees may deem future trials of PTAS unethical. Wider application of stent-assisted intracranial angioplasty appears unlikely to happen without more solid evidence from ongoing randomized controlled clinical trials. The trial is funded by The Netherlands Heart Foundation
